Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

Posting of Annual Report and Notice of AGM

Leeds, 4 June 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that the Annual Report and Accounts for the year ended 31 December 2018, the Notice of Annual General Meeting ("AGM") and the Form of Proxy have been sent to Shareholders. These documents will also be available on the Company's website, www.tissueregenix.com

Tissue Regenix Group AGM will be held at 10:00am on Thursday 27 June at the offices of DLA Piper UK LLP, Princes Exchange, Princes Street, Leeds, LS1 4BY.

For more Information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.